{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:59:28Z","timestamp":1792371568013,"version":"4.4.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.jconrel.2016.06.036","type":"journal-article","created":{"date-parts":[[2016,6,30]],"date-time":"2016-06-30T04:17:45Z","timestamp":1467260265000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":221,"special_numbering":"C","title":["Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles"],"prefix":"10.1016","volume":"237","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1834-2204","authenticated-orcid":false,"given":"Tsukasa","family":"Sugo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Terada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Oikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriya","family":"Kenjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Ogasawara-Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukimasa","family":"Makita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Imaichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumpei","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Otake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniko","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Teratani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Takagahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Ohtaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2016.06.036_bb0005","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0010","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1089\/nat.2012.0389","article-title":"Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo","volume":"22","author":"Wong","year":"2012","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0015","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0020","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrg3978","article-title":"Knocking down disease: a progress report on siRNA therapeutics","volume":"16","author":"Wittrup","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0025","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1152\/physrev.1987.67.2.520","article-title":"The physiology of transferrin and transferrin receptors","volume":"67","author":"Huebers","year":"1987","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0030","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/jcp.36.5.539","article-title":"Transferrin receptors in human tissues: their distribution and possible clinical relevance","volume":"36","author":"Gatter","year":"1983","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0035","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/jnr.490180206","article-title":"Receptor-mediated transcytosis of transferrin across the blood-brain barrier","volume":"18","author":"Fishman","year":"1987","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0040","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1073\/pnas.88.11.4771","article-title":"Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier","volume":"88","author":"Friden","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0045","doi-asserted-by":"crossref","first-page":"84ra44","DOI":"10.1126\/scitranslmed.3002230","article-title":"Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target","volume":"3","author":"Yu","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0050","first-page":"121","article-title":"Transferrin receptor as a potential therapeutic target","volume":"45","author":"Trowbridge","year":"1988","journal-title":"Prog. Allergy"},{"key":"10.1016\/j.jconrel.2016.06.036_bb0055","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/BF01116187","article-title":"Specific membrane receptors for diferric-transferrin in cultured rat skeletal myocytes and chick-embryo cardiac myocytes","volume":"1","author":"Fava","year":"1981","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0060","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1357-2725(99)00070-9","article-title":"The transferrin receptor: role in health and disease","volume":"31","author":"Ponka","year":"1999","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0065","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.V75.10.1903.1903","article-title":"Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects","volume":"75","author":"Cazzola","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2016.06.036_bb0070","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1073\/pnas.78.5.3039","article-title":"Human cell surface glycoprotein related to cell proliferation is the receptor for transferrin","volume":"78","author":"Trowbridge","year":"1981","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0075","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/294171a0","article-title":"Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumour cells","volume":"294","author":"Trowbridge","year":"1981","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2016.06.036_bb0080","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1124\/pr.54.4.561","article-title":"Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway","volume":"54","author":"Qian","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0085","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s002800050722","article-title":"Mechanism of action and spectrum of cell lines sensitive to a doxorubicin-transferrin conjugate","volume":"41","author":"Lai","year":"1998","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0090","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1073\/pnas.87.9.3410","article-title":"Transferrin-polycation conjugates as carriers for DNA uptake into cells","volume":"87","author":"Wagner","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0095","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1006\/mthe.2000.0043","article-title":"Targeted delivery of plasmid DNA to myogenic cells via transferrin-conjugated peptide nucleic acid","volume":"1","author":"Liang","year":"2000","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0100","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/mt.2013.32","article-title":"Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors","volume":"21","author":"Senzer","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0105","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1021\/bc034125f","article-title":"Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery","volume":"14","author":"Bellocq","year":"2003","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0110","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1349-7006.1998.tb00563.x","article-title":"Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues","volume":"89","author":"Noguchi","year":"1998","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0115","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s00018-008-8077-3","article-title":"Myostatin as a therapeutic target for musculoskeletal disease","volume":"65","author":"Bradley","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0120","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1532-5415.2007.01092.x","article-title":"Lower extremity ischemia, calf skeletal muscle characteristics, and functional impairment in peripheral arterial disease","volume":"55","author":"McDermott","year":"2007","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0125","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/01.CIR.87.2.413","article-title":"Chronic changes in skeletal muscle histology and function in peripheral arterial disease","volume":"87","author":"Regensteiner","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.jconrel.2016.06.036_bb0130","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/aje\/153.7.666","article-title":"Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study","volume":"153","author":"Hooi","year":"2001","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0135","article-title":"Fragmentation of immunoglobulin G","author":"Andrew","year":"2001","journal-title":"Curr. Protoc. Immunol."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0140","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1385\/1-59259-076-4:333","article-title":"How to make bispecific antibodies","volume":"40","author":"French","year":"2000","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0145","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0014-4827(89)90293-0","article-title":"Modulation of transferrin receptor expression and function by anti-transferrin receptor antibodies and antibody fragments","volume":"182","author":"Lesley","year":"1989","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0150","first-page":"2497","article-title":"Binding parameters and idiotypic profile of the whole immunoglobulin and Fab\u2032 fragments of murine monoclonal antibody to distinct determinants of the human high molecular weight-melanoma associated antigen","volume":"52","author":"Temponi","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0155","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4049\/jimmunol.143.3.787","article-title":"Transferrin receptor synthesis is an early event in B cell activation","volume":"143","author":"Futran","year":"1989","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0160","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1084\/jem.152.5.1430","article-title":"Novel surface antigen expressed on dividing cells but absent from nondividing cells","volume":"152","author":"Judd","year":"1980","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0165","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.vascn.2011.07.005","article-title":"Antibody drug conjugates \u2014 Trojan horses in the war on cancer","volume":"64","author":"Iyer","year":"2011","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.jconrel.2016.06.036_bb0170","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.biocel.2013.05.019","article-title":"Myostatin\/activin pathway antagonism: molecular basis and therapeutic potential","volume":"45","author":"Han","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0175","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nbt1101","article-title":"Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors","volume":"23","author":"Song","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0180","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1021\/cb200176v","article-title":"Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA","volume":"16","author":"Ma","year":"2011","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0185","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/nar\/gku1362","article-title":"Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates","volume":"43","author":"Cuellar","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0190","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1021\/cb501028c","article-title":"siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes","volume":"10","author":"Matsuda","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0195","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/gt.2008.24","article-title":"Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass","volume":"15","author":"Kinouchi","year":"2008","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0200","first-page":"3","article-title":"The mechanism of naked DNA uptake and expression","volume":"54","author":"Wolff","year":"2005","journal-title":"Adv. Genet."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0205","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/mt.2010.72","article-title":"Preclinical PK and PD studies on 2\u2032-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model","volume":"18","author":"Heemskerk","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0210","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzmab-DM1, an antibody-cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0215","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1089\/10430349950016816","article-title":"Role of endogenous endonucleases and tissue site in transfection and CpG-mediated immune activation after naked DNA injection","volume":"10","author":"Barry","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0220","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jjcc.2015.02.006","article-title":"Gene therapy for heart failure","volume":"66","author":"Greenberg","year":"2015","journal-title":"J. Cardiol."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0225","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2016.06.036_bb0230","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1440-169X.2010.01221.x","article-title":"Atelocollagen-mediated systemic administration of myostatin-targeting siRNA improves muscular atrophy in caveolin-3-deficient mice","volume":"53","author":"Kawakami","year":"2011","journal-title":"Develop. Growth Differ."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0235","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/dgd.12123","article-title":"Effectiveness of cationic liposome-mediated local delivery of myostatin-targeting small interfering RNA in vivo","volume":"56","author":"Mori","year":"2014","journal-title":"Develop. Growth Differ."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0240","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/gerona\/glp068","article-title":"Myostatin inhibition enhances the effects of exercise on performance and metabolic outcomes in aged mice","volume":"64A","author":"LeBrasseur","year":"2009","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011307","article-title":"Postnatal PPAR\u03b4 activation and myostatin inhibition exert distinct yet complimentary effects on the metabolic profile of obese insulin-resistant mice","volume":"5","author":"Bernardo","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2016.06.036_bb0250","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/1097-4652(200009)184:3<356::AID-JCP10>3.0.CO;2-R","article-title":"Myostatin regulation during skeletal muscle regeneration","volume":"184","author":"Kirk","year":"2000","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0255","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0006-291X(02)02953-4","article-title":"Inhibition of myostatin in adult mice increases skeletal muscle mass and strength","volume":"300","author":"Whittemore","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2016.06.036_bb0260","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/CIRCRESAHA.115.304185","article-title":"Myostatin regulates energy homeostasis in the heart and prevents heart failure","volume":"115","author":"Biesemann","year":"2014","journal-title":"Circ. Res."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916304138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916304138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T22:32:26Z","timestamp":1692397946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365916304138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":52,"alternative-id":["S0168365916304138"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2016.06.036","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2016.06.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}